Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.

Chin J Cancer · 2011 · PMC4012268 · PMID 21959045

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A separate observational cohort study examined the role of bevacizumab after disease progression in patients who did or did not received first-line bevacizumab and showed a trend towards longer OS in patients who had first- and second-line bevacizumab exposure (median OS, 21.7 months) than in patients who only received bevacizumab after progression (median OS, 17.5 months) [8] .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.